Hepatocellular Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: NRT6003 Injection Sponsors: Chengdu New Radiomedicine Technology Co. LTD. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Association of GSTP1 and CYP2B6 With Response and Survival Outcomes in HCC Patients.
Conditions: Hepatocellular Carcinoma Interventions: Drug: Doxorubicin Sponsors: Damanhour University; King Abdullah Bin Abdulaziz University Hospital; King Saud Bin Abdulaziz University for Health Sciences Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC
Conditions: Advanced Hepatocellular Carcinoma (HCC) Interventions: Drug: WGI-0301 at MTD/RP2D dose IV infusion, QW; Drug: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW; Drug: Sorafenib 400 mg PO, BID continuously; Drug: Sorafenib 400 mg PO, BID Sponsors: Zhejiang Haichang Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials

Open Versus Laparoscopic Ablation of Liver Malignancies
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases Interventions: Procedure: Laparoscopic ablation; Procedure: Open ablation Sponsors: Rigshospitalet, Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials

Open Versus Laparoscopic Ablation of Liver Malignancies: a Randomized, Controlled Multicenter Trial
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases Interventions: Procedure: Laparoscopic ablation; Procedure: Open ablation Sponsors: Rigshospitalet, Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials

Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular Interventions: Device: 166Holmium microspheres (QuiremSpheres ®) Sponsors: Imperial College London; Terumo Europe N.V. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
Conditions: Hepatocellular Carcinoma; Adjuvant Immunotherapy; Checkpoint Inhibitor Interventions: Drug: Anti-PD-1 monoclonal antibody Sponsors: Chen Xiaoping Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials

Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Conditions: Hepatocellular Carcinoma Resectable Sponsors: National Cancer Centre, Singapore; Singapore General Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials

Phase Ib/II Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Valemetostat; Drug: Atezolizumab; Drug: Bevacizumab Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Procedure: TOMOX-HAIC; Drug: Sintilimab; Drug: Bevacizumab Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Hypersplenism
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Combination Product: Splenectomy+Targeted therapy+ Immunotherapy Sponsors: Zhiyong Huang; Wuhan Union Hospital, China; Wuhan University; Renmin Hospital of Wuhan University; Taihe Hospital; Hubei Cancer Hospital; Xiangyang Central Hospital of Hubei Province; Wuhan Central Hospital; The Third People ' s Hospital of Yichang City Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+regorafenib Sponsors: Meng Chao Hepatobiliary Hospital of Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After Hepatectomy
Conditions: Liver Neoplasms Interventions: Other: late-evening snacks Sponsors: DU Yao Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials

Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Sponsors: Hebei Medical University Third Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials